IQVIA’s OCE Technology Platform Selected by Napo Pharmaceuticals to Increase Commercial Efficiency
November 29 2018 - 8:00AM
Business Wire
Innovative commercial engagement model for life
sciences companies improves customer alignment
IQVIA™ (NYSE:IQV) today announced that Napo Pharmaceuticals,
Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has
selected Orchestrated Customer Engagement (OCE), IQVIA
Technologies’ innovative commercial solutions suite, to support
Napo’s growing commercial organization and enable it to work more
closely with healthcare providers.
Napo will use the OCE technology platform for its product,
Mytesi®, an FDA-approved antidiarrheal indicated for the
symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART).
“Mytesi has a robust pipeline of potential follow-on
indications, and using IQVIA’s integrated solution, OCE, will help
our commercial teams better serve and work more closely with
healthcare providers,” said Robert Griffing, chief commercial
officer of Napo. “With improved efficiencies and advancements for
our field sales and home office teams, we can push our growing
commercial organization to the next level.”
IQVIA Technologies’ OCE transforms life sciences companies’
commercial operations from independent silos to insight-fueled,
orchestrated departments focused on highly relevant and contextual
customer engagement actions. By applying artificial intelligence
and intuitive user interfaces, the intraoperative OCE platform
increases efficiency across all functions, channels, and
stakeholders. This leads to reduced friction, enhanced
productivity, increased value, and better decision making among
customers.
“With IQVIA’s OCE, Napo saw the opportunity to have a
best-in-class technology suite, and we are thrilled they took
advantage of it,” said Tal Rosenberg, senior vice president, Global
Technology Solutions at IQVIA. “OCE will help Napo increase the
value of its customer interactions by offering a more intelligent
and coordinated customer experience that ultimately will yield
better health outcomes.”
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing the information that helps its customers
drive human health outcomes forward. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical
companies, medical researchers, government agencies, payers, and
other healthcare stakeholders tap into a deeper understanding of
diseases, human behaviors, and scientific advances, in an effort to
advance their path toward cures. To learn more, visit
www.iqvia.com.
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the
symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated
for the treatment of infectious diarrhea. Rule out infectious
etiologies of diarrhea before starting Mytesi. If infectious
etiologies are not considered, there is a risk that patients with
infectious etiologies will not receive the appropriate therapy and
their disease may worsen. In clinical studies, the most common
adverse reactions occurring at a rate greater than placebo were
upper respiratory tract infection (5.7%), bronchitis (3.9%), cough
(3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer,
the active ingredient in Mytesi, is a botanical (plant-based) drug
extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the Amazon rainforest.
Napo has established a sustainable harvesting program for
crofelemer to ensure a high degree of quality and ecological
integrity.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals
company focused on developing novel, sustainably derived
gastrointestinal products on a global basis. Our wholly-owned
subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and
commercializing proprietary human gastrointestinal pharmaceuticals
for the global marketplace from plants used traditionally in
rainforest areas. Our Mytesi® (crofelemer) product is approved
by the U.S. FDA for the symptomatic relief of noninfectious
diarrhea in adults with HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please
visit jaguar.health. For more information about Napo,
visit napopharma.com.
IQVIAFIN
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181129005374/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com)+1.484.567.6732Andrew Markwick, IQVIA
Investor Relations (andrew.markwick@iqvia.com)+1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Jul 2023 to Jul 2024